tenofovir disoproxil fumarate / Generic mfg. - LARVOL DELTA

Tenofovir-Associated Hypophosphatemic Osteomalacia in an HIV-Infected Patient: A Case Report. (PubMed, Cureus) - "Tenofovir disoproxil fumarate, a widely used nucleotide reverse transcriptase inhibitor in the treatment of human immunodeficiency virus infection, may rarely cause hypophosphatemia and osteomalacia due to proximal renal tubular dysfunction...After discontinuation of tenofovir and initiation of phosphate and active vitamin D supplementation, both clinical symptoms and laboratory abnormalities improved significantly. This case highlights hypophosphatemic osteomalacia as a potentially overlooked complication of tenofovir therapy."

Journal • Hematological Disorders • Human Immunodeficiency Virus • Infectious Disease • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Osteoporosis • Pain • Renal Disease • Rheumatology

Doravirine versus dolutegravir-based regimen in antiretroviral treatment-naive people living with HIV-1 (ANRS0392s ELDORADO): protocol for an international, open-label, randomised, non-inferiority, phase III trial. (PubMed, BMJ Open) - P3 | "Participants will be randomised in a 1:1 ratio to receive either DOR 100 mg once daily in combination with tenofovir disoproxil fumarate (TDF) (300 mg daily) plus lamivudine (3TC) (300 mg daily) or DTG (50 mg daily) in combination with TDF (300 mg once daily) plus either emtricitabine (FTC) (200 mg daily) or 3TC (300 mg daily). Results will also be communicated to policymakers, healthcare professionals, community stakeholders and study participants through appropriate dissemination activities, including policy briefs, stakeholder meetings and lay summaries on dedicated and easily accessible platforms. NCT06203132; EU-CT, 2023-508626-10-00."

Clinical protocol • Head-to-Head • Journal • P3 data • Cardiovascular • Diabetes • Human Immunodeficiency Virus • Hypertension • Infectious Disease • Metabolic Disorders

Effectiveness and safety of ainuovirine plus lamivudine and tenofovir DF in virologically suppressed people living with HIV-1: the 48-week results of a multicenter, real-world study. (PubMed, Antimicrob Agents Chemother) - "Although efavirenz (EFV)-based regimens have been widely used, current guidelines recommend integrase strand transfer inhibitor (INSTI)-based therapy as first-line...Virologically suppressed adults on a tenofovir disoproxil fumarate (TDF)/3TC+EFV regimen were either switched to TDF/3TC+ANV (ANV group) based on the physician's discretion or continued on TDF/3TC+EFV (EFV group)...Switching from EFV- to an ANV-based regimen effectively maintained VS and led to improved metabolic parameters, including less weight gain and a more favorable lipid profile. As an alternative switch strategy, the ANV-based regimen may be a more beneficial option for people living with HIV (PLWH) who are at high risk of weight-related or dyslipidemia-associated comorbidities."

Journal • Real-world evidence • Dyslipidemia • Human Immunodeficiency Virus • Infectious Disease • Metabolic Disorders • CD4 • CD8

Longitudinal Comparison of Bone, Growth and Biochemical Markers in Breastfed HIV-Exposed Uninfected and HIV-Unexposed Ugandan Children. (PubMed, J Bone Miner Res) - "However, studies report poorer growth and development in CHEU versus children HIV-unexposed uninfected (CHUU), raising concerns about maternal HIV and ART exposure, particularly Tenofovir Disoproxil Fumarate (TDF)...These findings suggest early onset growth deficits and altered bone metabolism in CHEU by 3 months of age, possibly linked to the TDF-containing ART initiated during pregnancy and/or disruptions in bone metabolism observed in their mothers. Further studies are needed to investigate the mechanisms and long-term implications for growth and bone health in CHEU."

Journal • Human Immunodeficiency Virus • Infectious Disease • Pediatrics

Evidence for the efficacy and safety of pre-exposure prophylaxis (PrEP) in all populations: a systematic review and meta-analysis. (PubMed, AIDS Care) - "PrEP (pre-exposure prophylaxis) is a medication used to prevent HIV infection, with the combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) being the most commonly used formulation...The proportion of general and gastrointestinal symptoms was 34%, sexually transmitted infections (STIs) 69%, other infections 32%, and dermatological AEs 5%. Overall, the findings support PrEP as an effective and safe medication for primary HIV prevention in all populations."

Journal • Retrospective data • Human Immunodeficiency Virus • Infectious Disease

Multivariable analysis of bone mass reduction risk prediction and anxiety status in male HIV/AIDS patients. (PubMed, Front Reprod Health) - "Univariate analysis revealed that six variables-age, body mass index (BMI), antiretroviral therapy (ART), tenofovir disoproxil fumarate (TDF) exposure, hepatitis B surface antigen (HBsAg) positivity, and hepatitis C virus antibody (Anti-HCV) positivity-were significantly associated with bone mass reduction (P < 0.05)...In addition, the high prevalence of anxiety symptoms among these patients warrants clinical attention. The developed risk prediction model for bone mass reduction demonstrated good discrimination and calibration, providing an effective tool for clinical practice to identify high-risk patients and facilitate early intervention."

Journal • Hepatitis B • Hepatitis C • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Mood Disorders • Osteoporosis • Psychiatry

Kidney disease screening at ART initiation among adults with HIV in Uganda: A missed priority for a high-risk population. (PubMed, PLOS Glob Public Health) - "People living with HIV (PWH) are at increased risk due to nephrotoxicity of antiretroviral therapy (ART), in part due to widespread use of tenofovir disoproxil fumarate...Kidney disease screening for PWH at ART initiation remains poor in Uganda, even when using a single creatinine test, particularly in rural clinics, highlighting critical challenges in translating national guidelines into practice. Future research should focus on understanding multilevel barriers to screening and evaluating strategies to improve guideline uptake."

Journal • Cardiovascular • Diabetes • Human Immunodeficiency Virus • Hypertension • Infectious Disease • Metabolic Disorders • Nephrology • Novel Coronavirus Disease • Renal Disease

Pegylated interferon-α-2b add-on therapy to renal function for chronic hepatitis B patients who were treated with tenofovir disoproxil fumarate: a retrospective real-world study. (PubMed, Virol J) - "PEG-IFN-α-2b might exert a protective effect against TDF-induced glomerular injury in CHB patients."

Journal • Real-world evidence • Retrospective data • Hepatitis B • Infectious Disease • Inflammation • B2M • IFNA1

Detectability of hepatitis B virus DNA in peripheral blood mononuclear cells following long-term nucleos(t)ide analogue therapy-induced sustained viral suppression. (PubMed, Eur J Gastroenterol Hepatol) - "HBV DNA may persist in PBMCs despite long-term nucleos(t)ide analogue therapy-induced sustained viral suppression. Pretreatment HBeAg positivity and elevated posttreatment qHBsAg can help identify patients at risk, highlighting the need to monitor extrahepatic reservoirs in CHB management."

Journal • Fibrosis • Hepatitis B • Immunology • Infectious Disease • Inflammation

Beyond DXA: Trabecular Bone Score, Quantitative Ultrasound and Bone Turnover Markers for Morphometric Vertebral Fracture Assessment in People Living with HIV. (PubMed, Diagnostics (Basel)) - "Degraded versus normal TBS was associated with older age (49.1 vs. 39.7 years), longer HIV duration and lower nadir CD4+ count, as well as more frequent tenofovir disoproxil fumarate exposure (66% vs. 52%; all p ≤ 0.04)...In sequential cross-sectional models for prevalent morphometric vertebral fractures, the area under the curve increased from 0.71 (clinical variables) to 0.79 after adding lumbar spine T-score and to 0.85 after adding TBS; adding CTX yielded 0.87 without a statistically significant incremental gain. In PLWH, TBS captures bone quality deficits and improves vertebral fracture risk discrimination beyond BMD, supporting its integration alongside DXA in routine HIV care."

Journal • Human Immunodeficiency Virus • Infectious Disease • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology • CD4

Vitamin D Status in People Living with HIV: Assessment of 25(OH)D Levels and Associated Factors-A Cross-Sectional Study. (PubMed, Metabolites) - "These findings indicate that monitoring vitamin D levels could be particularly relevant for patients with HIV with higher-risk profiles. However, our study included a relatively small number of participants, so further research in larger cohorts is needed to better understand these patterns."

Journal • Observational data • Genetic Disorders • Human Immunodeficiency Virus • Infectious Disease • Obesity • CD4

Evaluating the safety of prenatal HIV PrEP use: Perinatal outcomes from three cohort studies in Western Kenya. (PubMed, PLOS Glob Public Health) - "Existing data support the safety of daily oral tenofovir disoproxil fumarate (TDF)-based HIV pre-exposure prophylaxis (PrEP) use in pregnancy, yet ongoing monitoring is needed...All other perinatal outcomes were comparable by timing of HIV PrEP exposure. These findings support current guidelines recommending daily oral TDF-based HIV PrEP for pregnant and lactating women at risk of HIV."

Journal • Human Immunodeficiency Virus • Infectious Disease

Feasibility and Challenges in Implementing Mother-To-Child Transmission (PMTCT) of Hepatitis B Infection in Resource-Limited Settings in Malaysia. (PubMed, Asia Pac J Public Health) - "Those with high MTCT risk received tenofovir disoproxil fumarate from 28 weeks of gestation to 12 weeks postpartum...Risk factors included maternal age over 35, household exposure, and sexual transmission risk. These findings demonstrate the feasibility of WHO's PMTCT strategies in low-resource settings, supporting nationwide expansion in Malaysia."

Journal • Hepatitis B • Infectious Disease • Inflammation

qHBsAg outperforms ALT/qHBsAg ratio in predicting HBsAg seroclearance after cessation of entecavir versus tenofovir. (PubMed, Biomed J) - "A qHBsAg level <100 IU/mL at EOT is better predictor of HBsAg seroclearance than an ALT/qHBsAg ratio ≥0.2. Compared to TDF, entecavir was associated with higher rates of HBsAg seroclearance in patients with higher qHBsAg level or a lower ALT/qHBsAg ratio at EOT."

Journal • Fibrosis • Hepatitis B • Immunology • Infectious Disease • Inflammation

Prodrug strategies in developing antiviral nucleoside analogs. (PubMed, RSC Med Chem) - "Antiviral nucleoside prodrugs have garnered considerable interest in drug discovery, leading to the approval of key drugs such as remdesivir (SARS-CoV-2), Sovaldi (hepatitis C virus, HCV), and tenofovir disoproxil fumarate [hepatitis B virus (HBV) and human immunodeficiency viruses (HIV)]. Their success lies in improving the oral bioavailability and delivering the parent drug to the targeted tissues. This review focuses on the prodrugs of antiviral nucleosides evaluated in humans (approved, in development or terminated), providing an overview of the different approaches utilized and discussing their in vitro and in vivo benefits."

Journal • Review • Hepatitis B • Hepatitis C • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases

Postpartum maternal monitoring for renal safety related to tenofovir exposure during breastfeeding in the PROMISE 1077BF randomized trial. (PubMed, J Acquir Immune Defic Syndr) - "Although participants randomized to TDF-ART had larger decreases in CrCl from Entry compared with participants randomized to iNVP, differences attenuated overtime and were not clinically significant. TDF-containing ART had no observed safety concerns for maternal renal function during the postpartum period."

Journal • Human Immunodeficiency Virus • Infectious Disease • CD4

Toxicological evaluation of entricitabine and tenofovir disoproxyl fumarate, isolated and mixture, in cyanobacteria and microalgae. (PubMed, Sci Total Environ) - "This study evaluated the toxicity of the ARVs emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF), isolated, and combined, on the species cyanobacteria Microcystis novacekii and microalgae Chlorella vulgaris...The environmental risk assessment indicated a medium risk (RQ > 0.1) in untreated effluents. The results reinforce the importance of considering interactions between active ingredients and excipients in the ecotoxicology of drugs."

Journal

Tenofovir vs. entecavir in chronic hepatitis B: A retrospective cohort study of hepatocellular carcinoma risk in a tertiary hospital in southern Brazil. (PubMed, Braz J Infect Dis) - "Treatment with TDF was associated with a lower risk of HCC compared to ETV in the bivariate analysis, but this association lost significance in the multivariate analysis. These findings suggest that the initially observed protective effect of TDF against hepatic carcinogenesis may have been partially explained by confounding factors (cirrhosis/advanced fibrosis and age), as well as reflecting the limited sample size. Further studies are warranted to provide a more robust comparative evaluation of antiviral therapies."

Journal • Retrospective data • Cardiovascular • CNS Disorders • Fibrosis • Hepatic Encephalopathy • Hepatitis B • Hepatocellular Cancer • Hepatology • Human Immunodeficiency Virus • Hypertension • Immunology • Infectious Disease • Oncology • Portal Hypertension • Solid Tumor • Transplantation

Evaluating Renal Monitoring Practices for Tenofovir Disoproxil Fumarate-Based Therapies for Patients Living with HIV and Hepatitis B at a Large Federally Qualified Health Center (ASHP 2025) - No abstract available

Clinical • Hepatitis B • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation

The blocking efficacy and safety of tenofovir disoproxil fumarate tablets on mother-to-child transmission in pregnant women with high serum HBV DNA load: a retrospective cohort study. (PubMed, BMC Pregnancy Childbirth) - "TDF tablets can prevent MTCT of HBV in pregnant women with high HBV DNA loads. The treatment increases the seroconversion rates of HBV DNA, HBeAg, and HBsAg in mothers and infants, and shows a favorable safety profile without severe adverse outcomes."

Journal • Retrospective data • Hepatitis B • Infectious Disease • Inflammation

Modelling Micro-Elimination: Third-Trimester Tenofovir Prophylaxis for Perinatal Transmission of Hepatitis B in the Remote Dolpa District of Nepal. (PubMed, J Viral Hepat) - "Using mathematical modelling, we evaluated the impact of third-trimester tenofovir disoproxil fumarate (TDF) prophylaxis on HBV burden and estimated the time required to achieve HBV elimination in Dolpa...In geographically inaccessible settings, a micro-elimination approach using third-trimester TDF is an effective and equitable strategy for HBV control. This approach is likely to substantially reduce HBV burden and HBV-related mortality even before achieving elimination, while also addressing some of the challenges of immunoprophylaxis."

Journal • Hepatitis B • Infectious Disease • Inflammation

Different nucleos(t)ide analogs in resected hepatitis B virus-associated hepatocellular carcinoma: a systematic review. (PubMed, Front Pharmacol) - "Compared with the control group, antiviral therapies using telbivudine (HR [95% CrI] = 0.23 [0.12,0.44]), tenofovir disoproxil fumarate (HR [95% CrI] = 0.40 [0.30,0.52]), lamivudine (HR [95% CrI] = 0.50 [0.34, 0.75]), adefovir (HR [95% CrI] = 0.55 [0.38,0.79]), and entecavir (HR [95% CrI] = 0.55 [0.43,0.71]) significantly improved OS...When compared to other nucleos(t)ide analogs, telbivudine and tenofovir disoproxil fumarate exhibited the most notable effects. Identifier CRD42024612794."

Journal • Review • Hepatitis B • Hepatocellular Cancer • Infectious Disease • Oncology • Solid Tumor

Electrospun Tenofovir/Emtricitabine-Zein Nanofibers for Pre-Exposure Prophylaxis Platform against HIV through Vaginal Delivery. (PubMed, ACS Omega) - "Pre-exposure prophylaxis (PrEP) using tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) is a strategy recommended by the World Health Organization to prevent sexual transmission of HIV...The release studies showed controlled release of TDF and FTC for 24 h. Zein-based hybrid nanofibers incorporating mucoadhesive polymers represent a promising drug delivery system for the vaginal delivery of antiretroviral drugs as an effective and patient-compliant strategy for HIV prevention. This study provides a comprehensive formulation approach, combining zein with poly-(ethylene oxide) and polyvinylpyrrolidone to fine-tune nanofiber morphology, mechanical strength, mucoadhesion, and drug release properties for vaginal delivery."

Journal • Human Immunodeficiency Virus • Infectious Disease

Dapagliflozin treatment ameliorates oxidative stress, apoptosis and inflammation in tenofovir-induced nephrotoxicity in rats. (PubMed, Sci Rep) - "Tenofovir disoproxil fumarate is a widely prescribed component in antiretroviral therapy regimes frequently associated with nephrotoxicity. Furthermore, dapagliflozin treatment reduced inflammatory response and apoptotic cell death, marked by increased Bcl-2 expression and decreased levels of TLR4, NF-κB, pro-inflammatory cytokines, Bax, cytochrome c, and caspase-3. Dapagliflozin holds multifaceted renoprotective effects potentially offering a therapeutic strategy to slow the progression of kidney injury in tenofovir-induced nephrotoxicity."

IO biomarker • Journal • Preclinical • Inflammation • Renal Disease • BCL2 • CASP3 • TLR4

Ten-Year Follow-Up After 96 Weeks Treatment With Peginterferon Plus Tenofovir in Hepatitis D (HIDIT-II): Improved Clinical Outcome After Combination Therapy. (PubMed, United European Gastroenterol J) - P2 | "The long-term follow-up of this large randomised clinical trial demonstrates that combination therapy with TDF and virological response to PEG-IFNα-2a (undetectable HDV RNA and HBsAg loss) were associated with better clinical outcomes."

Clinical data • Journal • Fibrosis • Immunology • Inflammation • Liver Failure • IFNA1